Capillary leak syndrome in COVID-19 and post COVID-19 vaccines

[1] Tsibulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A, et al. Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. International Journal of Gynecologic Cancer. 2020; 30: 1667–1671.

[2] Roncati L, Gianotti G, Ambrogi E, Attolini G. COVID-19 in pregnancy. Clinical and Experimental Obstetrics & Gynecology. 2021; 48: 778.

[3] Roncati L, Ligabue G, Nasillo V, Lusenti B, Gennari W, Fabbiani L, et al. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients. Platelets. 2020; 31: 1085–1089.

[4] Gourd E. COVID-19 pandemic causes cervical cancer screening crisis. The Lancet Oncology. 2021; 22: 1060.

[5] Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020; 10: 783–791.

[6] Roncati L, Nasillo V, Lusenti B, Riva G. Signals of Th2 immune response from COVID-19 patients requiring intensive care. Annals of Hematology. 2020; 99: 1419–1420.

[7] Roncati L, Roncati M. Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic. Journal of Public Health Policy. 2021. (in press)

[8] McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Reports. 2021; 14: e244125.

[9] Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Reports. 2021; 14: e243629.

[10] Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirusvectored COVID-19 vaccine, ChAdOx1. BMJ Case Reports. 2021; 14: e242956.

[11] Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine. 2021; 384: 2202–2211.

[12] Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine. 2021; 384: 2124–2130.

[13] Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine. 2021; 384: 2092–2101.

[14] European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 2021. Available at: https://www.ema.europa.eu/en/documents/product-infor mation/vaxzevria-previously-covid-19-vaccine-astrazeneca-epa

r- product-information_en.pdf (Accessed: 19 July 2021).

[15] European Medicines Agency. COVID-19 Vaccine Janssen. 2021. Available at: https://www.ema.europa.eu/en/documents/produ ct-information/covid-19-vaccine-janssen-epar-product-infor mation_en.pdf (Accessed: 4 August 2021).

[16] European Medicines Agency. Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. 2021. Available at: https://www.ema.europa.eu/en/news/vaxzevria-ema-a dvises-against-use-people-history-capillary-leak-syndrome (Accessed: 11 June 2021).

[17] European Medicines Agency. EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome. 2021. Available at: https: //www.ema.europa.eu/en/news/ema-advises-against-use-cov id-19-vaccine-janssen-people-history-capillary-leak-syndrome (Accessed: 9 July 2021).

[18] Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International. 2017; 92: 37–46.

[19] Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, et al. Idiopathic systemic capillary leak syndrome (Clarkson’s disease): the Mayo clinic experience. Mayo Clinic Proceedings. 2010; 85: 905–912.

[20] Pineton de Chambrun M, Luyt C, Beloncle F, Gousseff M, Mauhin W, Argaud L, et al. The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. Critical Care Medicine. 2017; 45: 1216–1223.

[21] Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. The American Journal of Medicine. 1960; 29: 193–216.

[22] Pineton de Chambrun M, Cohen-Aubart F, Donker DW, Cariou P, Luyt C, Combes A, et al. SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson’s Disease). The American Journal of Medicine. 2020; 133: e663–e664.

[23] Cheung PC, Eisch AR, Maleque N, Polly DM, Auld SC, Druey KM. Fatal exacerbations of systemic capillary leak syndrome complicating coronavirus disease. Emerging Infectious Diseases. 2021. (in press)

[24] Bahloul M, Ketata W, Lahyeni D, Mayoufi H, Kotti A, Smaoui F, et al. Pulmonary capillary leak syndrome following COVID-19 virus infection. Journal of Medical Virology. 2021; 93: 94–96.

[25] Case R, Ramaniuk A, Martin P, Simpson PJ, Harden C, Ataya A. Systemic Capillary Leak Syndrome Secondary to Coronavirus Disease 2019. Chest. 2020; 158: e267–e268.

[26] Lacout C, Rogez J, Orvain C, Nicot C, Rony L, Julien H, et al. A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19. Rheumatology. 2021; 60: e19–e20.

[27] Wu MA, Fossali T, Pandolfi L, Carsana L, Ottolina D, Frangipane V, et al. Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary leakage. Journal of Internal Medicine. 2021; 289: 861–872.

[28] Beber A, Dellai F, Abdel Jaber M, Peterlana D, Brunori G, Maino A. Systemic capillary leak syndrome triggered by SARS-CoV2 infection: case report and systematic review. Scandinavian Journal of Rheumatology. 2021. (in press)

[29] Roncati L, Corsi L. Nucleoside-modified messenger RNA COVID-19 vaccine platform. Journal of Medical Virology. 2021; 93: 4054–4057.

[30] Roncati L, Gallo G, Manenti A, Palmieri B. Renin-angiotensin system: the unexpected flaw inside the human immune system revealed by SARS-CoV-2. Medical Hypotheses. 2020; 140: 109686.

[31] Roncati L, Palmieri B. What about the original antigenic sin of the humans versus SARS-CoV-2? Medical Hypotheses. 2020; 142: 109824.

[32] Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, et al. Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: a case series. Annals of Internal Medicine. 2021. (in press)

[33] Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland V, Queyrel V, et al. Highdose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Critical Care Medicine. 2008; 36: 2184–2187.

[34] Xie Z, Chan EC, Long LM, Nelson C, Druey KM. Highdose Intravenous Immunoglobulin Therapy for Systemic Capillary Leak Syndrome (Clarkson Disease). The American Journal of Medicine. 2015; 128: 91–95.